Persistent tardive rebound panic disorder, rebound anxiety and insomnia following paroxetine withdrawal: a review of rebound-withdrawal phenomena
- PMID: 16456219
Persistent tardive rebound panic disorder, rebound anxiety and insomnia following paroxetine withdrawal: a review of rebound-withdrawal phenomena
Abstract
Objective: To describe tardive rebound anxiety phenomena (panic, anxiety and insomnia) following abrupt paroxetine discontinuation.
Method: Case report, with comprehensive literature review on rebound and withdrawal phenomena associated with psychotropic medications.
Results: Three different discontinuation syndromes with psychotropics are described: (1) new-onset CNS-depressant type withdrawal symptoms (minor and major); (2) rebound syndromes; and (3) supersensitivity symptoms. Abrupt paroxetine discontinuation has been well described and fits the first category. Tardive rebound panic disorder-phenomena with paroxetine has some features of the supersensitivity category.
Conclusion: Chronic paroxetine treatment may lead to 5-HT2-receptor down regulation, with desensitization of 5-HT1A and 5-HT2 receptors, which may contribute to tardive rebound symptoms upon abrupt withdrawal. Early reports suggest that genetic factors may also contribute to withdrawal symptoms in susceptible individuals. Cholinergic rebound may also occur and could explain tardive insomnia and anxiety in paroxetine withdrawal.
Similar articles
-
Thioridazine withdrawal-induced behavioral deterioration treated with clonidine: two case reports.Ment Retard. 1995 Aug;33(4):221-5. Ment Retard. 1995. PMID: 7565144
-
[Withdrawal reactions after clomipramine].Harefuah. 1992 Oct;123(7-8):252-5, 307. Harefuah. 1992. PMID: 1459499 Hebrew.
-
Rebound insomnia in neuroleptic drug withdrawal neurophysiologic characteristics.Pharmacopsychiatry. 1987 May;20(3):116-9. doi: 10.1055/s-2007-1017087. Pharmacopsychiatry. 1987. PMID: 2885865
-
[Side effects of benzodiazepines: "rebound" anxiety and insomnia].Clin Ter. 1981 Dec 15;99(5):461-70. Clin Ter. 1981. PMID: 7037272 Review. Italian. No abstract available.
-
Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound.J Clin Psychiatry. 2004;65 Suppl 5:7-12. J Clin Psychiatry. 2004. PMID: 15078112 Review.
Cited by
-
What I have learnt from helping thousands of people taper off antidepressants and other psychotropic medications.Ther Adv Psychopharmacol. 2021 Mar 16;11:2045125321991274. doi: 10.1177/2045125321991274. eCollection 2021. Ther Adv Psychopharmacol. 2021. PMID: 33796265 Free PMC article. Review.
-
Mechanisms of SSRI Therapy and Discontinuation.Curr Top Behav Neurosci. 2024;66:21-47. doi: 10.1007/7854_2023_452. Curr Top Behav Neurosci. 2024. PMID: 37955823 Review.
-
Dependence, withdrawal and rebound of CNS drugs: an update and regulatory considerations for new drugs development.Brain Commun. 2019 Oct 16;1(1):fcz025. doi: 10.1093/braincomms/fcz025. eCollection 2019. Brain Commun. 2019. PMID: 32954266 Free PMC article. Review.
-
Post-acute withdrawal syndrome (PAWS) after stopping antidepressants: a systematic review with meta-narrative synthesis.Epidemiol Psychiatr Sci. 2025 May 13;34:e29. doi: 10.1017/S204579602500023X. Epidemiol Psychiatr Sci. 2025. PMID: 40357765 Free PMC article.
-
A case report of onset of tinnitus following discontinuation of antidepressant and a review of the literature.Prim Care Companion CNS Disord. 2012;14(1):PCC.11br01218. doi: 10.4088/PCC.11br01218. Epub 2012 Feb 16. Prim Care Companion CNS Disord. 2012. PMID: 22690352 Free PMC article.